The total return over the past 12 months is -71.12% vs. +16.94% for the S&P 500. So far it's up -70.65% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (71.12%) | (64.76%) | N/A | N/A | N/A | N/A |
| Total Return CAGR | (71.12%) | (64.76%) | N/A | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Neumora Therapeutics, Inc. Common Stock (NMRA)
| Year | Start price | End price | NMRA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.79 | $0.53 | (70.65%) | +14.51% | (85.16%) |
| 2025 | $10.60 | $1.79 | (83.11%) | +17.72% | (100.83%) |
| 2024 | $17.05 | $10.60 | (37.83%) | +24.89% | (62.72%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
